Gladius Capital Management’s AbbVie ABBV Stock Holding History

Gladius Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$12.1M	Buy	55,600 +18,300	+49%	+$4.06M	0.54%	48
2025 Q4	$8.52M	Buy	37,300 +22,100	+145%	+$5.03M	0.47%	48
2025 Q3	$3.52M	Buy	+15,200	New	+$3.1M	0.37%	58
2024 Q1	–	Sell	-9,700	Closed	-$1.5M	–	308
2023 Q4	$1.5M	Sell	9,700 -18,000	-65%	-$2.62M	0.23%	68
2023 Q3	$4.13M	Buy	27,700 +8,700	+46%	+$1.28M	0.17%	92
2023 Q2	$2.56M	Buy	19,000 +4,700	+33%	+$689K	0.13%	72
2023 Q1	$2.28M	Buy	+14,300	New	+$2.19M	0.13%	79
2022 Q1	–	Sell	-2,700	Closed	-$366K	–	268
2021 Q4	$366K	Sell	2,700 -1,500	-36%	-$177K	0.03%	135
2021 Q3	$454K	Hold	4,200	–	–	0.03%	78
2021 Q2	$474K	Sell	4,200 -28,700	-87%	-$3.23M	0.04%	84
2021 Q1	$3.56M	Buy	32,900 +6,100	+23%	+$652K	0.13%	108
2020 Q4	$2.87M	Buy	26,800 +19,500	+267%	+$1.87M	0.14%	119
2020 Q3	$640K	Buy	+7,300	New	+$687K	0.06%	115

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Gladius Capital Management's ABBV Position: Q1 2026 in Review

Gladius Capital Management reduced its AbbVie (ABBV) stake by 48% in Q1 2026, selling an estimated $809K and leaving 3,925 shares worth $854K. The position accounts for 0.04% of the portfolio, ranked #96.

Gladius Capital Management first reported a position in ABBV in Q2 2018 and has held it in 26 quarters since. The position peaked at $2.53M in Q4 2018. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Gladius Capital Management held 3,925 shares of AbbVie worth $854K as of Q1 2026.
Gladius Capital Management sold 3,647 AbbVie shares in Q1 2026, an estimated $809K.
AbbVie made up 0.04% of Gladius Capital Management's portfolio in Q1 2026, its #96 holding.
Gladius Capital Management first reported a position in AbbVie in Q2 2018 and has held it in 26 quarters since.
Gladius Capital Management's AbbVie position peaked at $2.53M in Q4 2018.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Gladius Capital Management's 13F filing for Q1 2026, filed 7 May 2026.